CBAY Live signals | Maximize Profits with Getagraph.com

BUY 51923 min ago

@ $32.47

Issued: 20 Mar 2024 @ 14:01

Return: 0.03%

Previous signal: Mar 19 - 14:47

Previous signal: Sell

Return: -0.03 %

Live Chart Being Loaded With Signals

Commentary (21 Mar 2024 @ 16:00):

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases...

Stats
Today's Volume	0.00
Average Volume	4.16M
Market Cap	3.73B
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.320 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-32.81
ATR14	$0.00700 (0.02%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-22	Loewy Caroline M	Sell	30 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	15 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	7 500	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	16 000	Employee Stock Option (right to buy)
2024-03-22	Loewy Caroline M	Sell	27 705	Employee Stock Option (right to buy)

INSIDER POWER
-97.48
Last 100 transactions
Buy: 127 470 \| Sell: 9 848 383

Volume Correlation

Long: -0.17 (neutral)

Short: -0.63 (weak negative)

Signal:(46.979) Neutral

Cymabay Therapeutics Inc Correlation

10 Most Positive Correlations
XPDB	0.96
ROCL	0.956
HWEL	0.955
IXAQ	0.953
GDNR	0.953
ARTEU	0.952
VMGA	0.952
FNVT	0.952
AVAC	0.951
PWUP	0.951

10 Most Negative Correlations
RMRM	-0.983
ASPS	-0.952
BFC	-0.945
EVLO	-0.943
CLFD	-0.942
CREG	-0.941
YJ	-0.941
STAB	-0.941
SYBT	-0.939
MMAT	-0.936

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Cymabay Therapeutics Inc Correlation - Currency/Commodity

0.00
( neutral )

0.17
( neutral )

Cymabay Therapeutics Inc Financials

Annual	2023
Revenue:	$31.07M
Gross Profit:	$30.39M (97.81 %)
EPS:	$-0.990

Q4	2023
Revenue:	$57 000.00
Gross Profit:	$1 000.00 (1.75 %)
EPS:	$-0.370

Q3	2023
Revenue:	$0
Gross Profit:	$-215 000 (0.00 %)
EPS:	$-0.320

Q2	2023
Revenue:	$31.02M
Gross Profit:	$30.81M (99.32 %)
EPS:	$-0.00790

Financial Reports:

No articles found.

Cymabay Therapeutics Inc

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.